DrugLogic™, Inc. announces Qscan™- ERM.

Reston, Virginia, 26 June 2005. DrugLogic™, Inc. is pleased to announce Qscan™- ERM, the Enterprise Risk Management system that provides complete support for the pharmacovigilance workflow process. Qscan-ERM will be available this summer for all current Qscan™ implementations; Qscan™ -Internal (proprietary data application, previously marketed as Qscan™-PRO) as well as for selected installations of Qscan™ FDA (FOI, AERS data) and Qscan™ World (WHO-UMC data). Qscan™ has been the DrugLogic flagship product for over six years. It is used to monitor and analyze both drug company proprietary adverse event data and publicly available data. New features of Qscan™- ERM will be demonstrated at the Drug Information Association annual conference in Washington D.C

Qscan™- ERM is a new system that incorporates workspace, browsing, collaboration and research tools integrated to support the complete drug safety workflows. Qscan™- ERM integrates seamlessly and quickly with your existing data-capture system, minimizing deployment, validation and training time. It is a bridge to external and internal adverse event data, as well as exposure, label and other epidemiology data.

“Safety is a term not taken lightly under the emerging pharmacovigilance microscope…a term that MUST bring renewed confidence to the public,” says Victor Gogolak, President of DrugLogic®. “Pharmaceutical companies are increasing their vigilance with regard to safety, and DrugLogic is committed to supporting them.”

The goal of DrugLogic®’s Qscan™- ERM in incorporating workflow for pharmacovigilance into the Qscan™ system is to support the practical needs of drug safety teams. Those needs are:

• To define the roles of the drug safety team
• To establish the thresholds for automatic signal generation (event or issue)
• To provide easy management tracking of the issues
  - The assigned parties
  - Progress on the events and research
• To support the analytical process (research tools, hypothesis, communication amongst team etc. This is Qscan classic.)
• To provide for documentation and,
• To provide closure and an audit trail for the closure of issues

The classic Qscan™ application is seamlessly merged into the new system, and provides the basis for thresholding, analytics with eight algorithm engines and the immediate availability of data from the adverse event database of record. The three modules- Workspace, Browser, and Research Tools – share a common interface. Thresholds, for example can be set using any parameter, and both automatic and manual alerts are integrated into an “Issue Management” system. End-to-end tracking and audit are provided, all in a secure, web-based application.

About DrugLogic, Inc.
DrugLogic®, Inc. specializes in developing analytical tools and enterprise process support systems for managing risks related to drug safety issues. DrugLogic is dedicated to designing, developing and delivering products that provide the latest innovations and state-of-the art solutions in support of pharmacovigilance and drug safety surveillance practices for both pharmaceutical and biotech companies. Its proprietary Qscan™ product monitors both company proprietary adverse event data and publicly available data sources. For more information, visit www.druglogic.com.

Contacts: